Hook & thesis
TG Therapeutics has moved beyond the narrative stage and into commercial proof. BRIUMVI, the company's multiple sclerosis therapy, is driving a step-change in revenue: U.S. net sales of $119.7 million in Q1 2025 and accelerating growth in Q2 that produced a 91% year-over-year jump and prompted management to raise full-year revenue guidance to $585 million. That kind of top-line momentum, paired with a reasonable P/E near 11 and improving technicals, makes TGTX a Strong Buy on a trade basis.
This is an actionable long trade: enter at the current price, use a stop below the 52-week low to protect against downside surprises, and target a move that recognizes both the company's commercial optionality and the stock's historical highs. The plan assumes continued BRIUMVI share gains, disciplined commercial execution, and steady margin expansion over the next 180 trading days.
What the company does and why the market should care
TG Therapeutics is a commercial-stage biopharma focused on B-cell driven diseases, primarily multiple sclerosis (MS). Its commercial engine is BRIUMVI, approved in 2022 and now the primary revenue driver. The company also holds other pipeline assets (TG-1501, TG-1701, Ublituximab, Umbralisib) but the market is valuing TGTX largely on BRIUMVI's trajectory.
Why investors should pay attention: BRIUMVI is scaling rapidly. Management reported $119.7 million in U.S. net sales in Q1 2025 (reported 05/05/2025) and flagged similarly strong Q2 2025 growth, lifting full-year revenue guidance to $585 million (reported 08/04/2025). For a company with a market capitalization roughly in the $4.7-4.9 billion range, converting BRIUMVI into a $500m+ revenue stream within a year materially de-risks the stock versus a pure-play development name.
Key financial and market facts
| Metric | Value |
|---|---|
| Current price | $30.09 |
| Market cap (snapshot) | $4.78B |
| Enterprise value | $5.08B |
| Trailing EPS | $2.82 |
| P/E | ~11.1 |
| Price-to-sales | ~9.2 |
| Free cash flow (most recent) | -$70.2M |
| Q1 2025 BRIUMVI U.S. net sales | $119.7M (reported 05/05/2025) |
| 2025 revenue guidance (revised) | $585M (raised 08/04/2025) |
Why the numbers matter
The company is already generating substantial revenue from a single product and guiding to a mid-single-digit to high-single-digit revenue figure in the hundreds of millions for the year. With EPS at about $2.82 and a P/E near 11, the market is effectively giving a modest multiple to meaningful commercialization success. That multiple looks reasonable if the BRIUMVI ramp continues and margins expand as fixed SG&A costs absorb through higher sales.
Technical backdrop
Technically, TGTX sits near $30.09 with a 50-day simple moving average at $29.91 and an RSI of ~52, indicating neither overbought nor oversold conditions. MACD is signaling bullish momentum. Short interest remains elevated (roughly 29.3M shares short as of 02/13/2026 with days to cover near 19), which creates the potential for volatility but also a pronounced upside if quarterlies or guidance beats expectations.
Catalysts to watch (2-5)
- Upcoming quarterly releases - any continued sequential BRIUMVI sales beats and margin expansion would be an immediate catalyst.
- New dosing/regimen updates - management has flagged subcutaneous BRIUMVI development; positive clinical/regulatory news would broaden the commercial profile.
- Label expansion or new indication moves - progress toward treating progressive MS or additional B-cell disorders would materially increase addressable market.
- Commercial footprint expansion and payer adoption - faster formulary access and stronger prescribing trends vs peers could accelerate revenue beyond current guidance.
Valuation framing
The current market cap near $4.8 billion implies heavy expectations for sustained BRIUMVI sales and profitable scaling. On a P/E of roughly 11 and trailing EPS of $2.82, the stock is not sporting an extreme multiple relative to high-growth biotechs; in contrast, the price-to-sales metric (~9.2) is elevated because revenue is still young relative to earnings. Enterprise multiples show EV/sales near 9.5 and EV/EBITDA around 49x, reflecting early-stage commercial margins and negative free cash flow of about -$70 million.
Put simply: the market is paying for future growth but already rewarding realized earnings today. If management hits or exceeds the raised $585 million revenue guide and demonstrates margin progress, a move back toward prior highs (the 52-week high was $46.48 on 05/01/2025) is reasonable — hence the target below.
Trade plan (actionable)
Thesis: Buy TGTX to capture upside from continued BRIUMVI roll-out and margin expansion. This is a long trade with a horizon aligned to ongoing commercial developments and potential label/indication expansion.
Entry price: 30.09
Target: 46.00
Stop loss: 25.50
Horizon: long term (180 trading days) - expect the bulk of the upside to materialize over multiple quarters as sales trends and margin improvements are reported and commercial execution scales. This horizon gives time for sequential sales beats and prepares for potential positive regulatory or label developments.
Position sizing note: Given the biotechnology/commercial execution risk, size positions so loss to the stop is within your risk tolerance. The stop at $25.50 sits below the recent swing low and the 52-week low ($25.28), offering a clear technical cut-off for the thesis failing.
Risks and counterarguments
- Commercial execution risk: BRIUMVI adoption could slow if competing therapies gain share or if payers restrict access. Slower sales would pressure the stock quickly.
- Regulatory/label risk: Any negative regulatory news around dosing changes, safety signals, or label limitations would be a major headwind.
- Financial risk: Free cash flow remains negative (~-$70.2M) and the company will need to convert operating leverage into positive cash flow; continued losses could force equity raises, diluting existing holders.
- Market technical risk: Short interest is sizable (roughly 29M shares), creating the possibility of sharp downside moves if sentiment flips or there is coordinated short pressure.
- Valuation sensitivity: The stock trades at elevated price-to-sales and EV/EBITDA multiples; if revenue growth disappoints, multiples can compress quickly even if earnings remain positive in the short term.
Counterargument to the bullish case
One reasonable counterargument: a commercial-stage biotech with strong initial sales can still fail to sustain growth if competition or payer dynamics cap uptake. If BRIUMVI's growth plateaus or new safety/efficacy data from competitors shifts prescribing patterns, the market could de-rate the company sharply despite its current EPS base. That outcome would invalidate the long trade thesis and likely push price below the stop.
Conclusion and what would change my mind
I rate TGTX a Strong Buy for an event-driven, trade-oriented investor with a 180-trading-day horizon. The combination of clear sales momentum ($119.7M in Q1 2025, 91% growth in Q2 2025 leading to a $585M guide), an attractive P/E near 11, and bullish technical indicators gives a favorable reward/risk when protected with a disciplined stop at $25.50.
What would change my mind: if sequential BRIUMVI sales decelerate materially versus guidance, if the company reports a new negative safety signal, or if management shifts guidance lower, I would close the position immediately. Conversely, sustained beats and margin improvement would reinforce the thesis and justify raising targets toward or above the $46.48 52-week high.
Key monitoring points
- Quarterly sales and margin progression vs the $585M guide.
- Payer access and formulary wins or losses for BRIUMVI.
- Clinical/regulatory updates on subcutaneous dosing and any progressive MS programs.
- Short interest and sudden spikes in days-to-cover which could indicate rising hedge activity.
Trade with a plan: enter at $30.09, stop at $25.50, target $46.00, and reassess with each quarterly print. The path to the target is straightforward: continued BRIUMVI adoption and margin leverage. The path to the stop is equally clear: slower uptake, payer pushback, or negative data. Manage position size accordingly.
Bottom line: BRIUMVI is no longer just potential — it's producing real revenue and shaping TGTX's valuation. For traders willing to accept biotech volatility, the risk/reward looks compelling from these levels.